chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Pt had itching about 50 minutes after getting the Pfizer covid vaccine. Pt waited the time requested and was thankfully still shopping with her mother and brother in the store when the reaction developed. Pt was given 50mg of liquid diphenhydramine. I discussed calling 911 with the family and they said they would prefer we did not if possible. She has food allergies, which were discussed before giving the vaccine and she is used to having reactions, she also knows what anaphylaxis feels like and could tell that was not the reaction she was having. After discussing with the family and consulting with my market direction I decided to not call 911 immediately but let them know that if the diphenhydramine was not helping quickly I would make the call. I observed the patient for 30+ minutes with an EpiPen on my person in case she showed any signs of worsening. She improved visibly while getting drowsy from the antihistamine. After she had stabilized for some time and the patient and her family was also comfortable with her improvement I allowed her to depart the pharmacy with a request to keep her EpiPen close and call 911 if things worsen or the EpiPen became necessary.
formication 1 hour after vaccination. no signs of rash or redness. no trouble breathing. reported symptoms similiar to  patient allergic reaction to sulfa medications
Low grade fever of 99 to 100.4 degrees for eleven days after first dose; This spontaneous case was reported by a consumer and describes the occurrence of PYREXIA (Low grade fever of 99 to 100.4 degrees for eleven days after first dose) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 039A21A) for COVID-19 vaccination.     Concurrent medical conditions included Back pain. Concomitant products included FENTANYL CITRATE (NARCO) for Back pain.    On 03-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 04-Mar-2021, the patient experienced PYREXIA (Low grade fever of 99 to 100.4 degrees for eleven days after first dose). On 15-Mar-2021, PYREXIA (Low grade fever of 99 to 100.4 degrees for eleven days after first dose) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 04-Mar-2021, Body temperature: 99 to 100.4 (High) 99 to 100.4 degrees.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No treatment information was provided.
Pneumonia shot from vaccine produced by Merck. Hives on shoulders, spreading to chest, back stomach and upper thighs. Hives present at this date - 9/14/2010 - but deduced in number. I do NOT want to take Predisone due to side effects.
On other hand my injection site pain was not as bad as first dose; This is a spontaneous report from a contactable 27-year-old female pharmacist reported for herself that: This is a spontaneous report from a contactable pharmacist reported for herself. A 27-years-old non pregnant female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, Batch/Lot Number: EW0171), via an unspecified route of administration, administered in Arm Right on 24Apr2021 17:30 (at the age of 27-year-old) as dose 1, single for covid-19 immunisation. Medical history included polycystic ovaries from an unknown date and unknown if ongoing PCOS, nephrolithiasis from an unknown date and unknown if ongoing. The patient's concomitant medications were not reported. Patient was not pregnant at the time of vaccination. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On an unspecified date in 2021, the patient experienced on other hand my injection site pain was not as bad as first dose. The events were considered as non serious. The outcome of the event was unknown.  Follow-up attempts completed. No further information is expected.
Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021; Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021; This spontaneous case was reported by an other health care professional and describes the occurrence of POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) and PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) in a 69-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 035C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 27-Oct-2021 at 9:25 AM, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. On 27-Oct-2021 at 9:25 AM, the patient experienced POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021). On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021). At the time of the report, POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) and PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Age of patient was reported as 69.67.   No concomitant medications were reported.  Batch number 035C21A was administered on 27-Oct-2021 with temperature between 29 to 32 from 09:00 AM to 10:00 AM. This vial was moved to fridge on 29-Sep-2021 and 05-Oct-2021 and beyond use date for the vial was reported as 29-Oct-2021 and 04-Nov-2021. Product moved to clinic on 27-Oct-2021.  Vial was in cooler storage and was not in frozen storage during high-pace COVID-19 vaccination at around 2021. Vials were only punctured right before administration. Vaccines were not frozen at time of administration. It was reported that each time a vial was put into a cooler, sometimes there was a period of 1 hour or 1 hour and a half approximately, when temperature data logger registered a temperature of 34- or 35-degree Fahrenheit. Temperature recordings were taken using a Fisher brand traceable temperature monitor at every hour.  No treatment medications were reported.
Patient vaccinated on 06/24/2017 onset of symptoms began about 07/01/2017 on scalp and forehead. Patient went to E.R. on 07/04/17 diagnosed with shingles by MD and given antivirals. Follow up with primary MD on 07/07/17 and given more meds.
Red (day 1). Swelling (day 2). Bumps, swelling, red (day 3). Bigger bumps, swelling red (day 4).
Patient was slow response after receiving two vaccines. HEP A AND VARICELLA. Nurse assisted patient to floor. C/o of light headedness and numbness with some confusion.
I got my shots at the county offices that night I had so much pain in my right arm I couldn't use it. I was so out of it I thought it would go away, it didn't I went to my doctor. She gave me an anti inflammatory shot & pain pill. I did not go to my follow up, since my insurance wasn't active. The woman that gave me the shot would not file a report. So I do know the manufacturer or anything. My arm still hurts. I think all reactions should be reported. The nurse that gave me the shot gave it too high and she didn't seem to give a crap.
11/14/06 830AM Zostavax SQ LA. Approximately 24 hours later, injection site was firm 1"x1" oblong, tender. 11/15/06 Noticed tender and firmarca at injection site. 11/16/06 5PM Injection site measures 60mmx20mm - red, hot to touch, firmarca 30mmx18mm and darker red. ? Blister.
inappropriate schedule of vaccine adminstration; This spontaneous case was reported by a pharmacist and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (inappropriate schedule of vaccine adminstration) in a 29-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 022B21A) for COVID-19 vaccination.     No Medical History information was reported.   On 22-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 10-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 10-May-2021, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (inappropriate schedule of vaccine adminstration). At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (inappropriate schedule of vaccine adminstration) outcome was unknown. Not Provided      For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Pharmacist called on 10May2021 and said that she had a patient who received 1st dose of Moderna Covid 19 Vaccine on 22Apr2021and 2nd dose on 10May2021. She said she received 2nd dose less than 25 days time period. She wanted to know if it is safe for her to get 2nd dose this earlier
pt cried p/shot all day;had shot about 830AM;started crying about 9AM;cried 2 1/2 to 3hrs;tried to feed;refused to feed, fell asleep;slept about 5mins then started to cry again;cont to cry till approx 8PM; fussy
1:22 pm pt c/o of heart racing, numbness of tongue and lips. Xarm feeling numb. 2:20 Symptoms resolving after benadryl & pepcid admin. 48 y/o female who presents with heart racing & numbness of tongues & lips. No other complaints No hx of allergic RXN Exam unremarkable Plan - home with observation. Possible allergic reaction - mild
Information has been received concerning a female with a history of malignant neoplasms who was vaccinated with Zostavax (Oka/Merck).  Subsequently the patient experienced a rash.  Additional information is not expected.
High fever - already 3 days; This is a spontaneous report from a contactable consumer, the patient. A 33-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left  arm on 08Apr2021 at 15:30 (at the age of 33-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. The patient did not receive any medication within two weeks of vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 18Mar2021 at 15:30 (at the age of 33-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 08Apr2021 at 21:30, the patient experienced high fever - already 3 days. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the event. The clinical outcome of the event high fever - already 3 days was not recovered at the time of this report.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Developed chest pain and SOB.  Had negative ECG, enzymes and echo but had classic pain within timeframe consistent with post vaccinal pericarditis according to criteria set forth by the CDC/DoD.  See attached cardiology evaluation.  Symptom: Chest Pain.  Symptom: Dyspnea.  6/10/08 Reviewed medical records of 3/20-3/25/2008. FINAL DX: Pericarditis Records reveal patient experienced chest pain & heaviness 12 days s/p smallpox, anthrax & rabies vaccines.  NSAIDS relieved pain but w/o pain returned.  Cardio consult done.
Refused to move left arm, complained of pain. Area red and swollen, warm to touch, 7x9 cm erythema, 4x5 cm induration. Prescribed Naprosyn 5cc BID.
suspected vaccination failure; shingles / had it twice; This case was reported by a consumer via interactive digital media and described the occurrence of suspected vaccination failure in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   Co-suspect products included Herpes zoster (Shingles vaccine) for prophylaxis and COVID-19 VACCINE for prophylaxis.   The patient's past medical history included hip replacement. Previously administered products included Covid 19 vaccine (received a dose on an unknown date).   On an unknown date, the patient received the 2nd dose of Shingles vaccine, the 1st dose of Shingles vaccine and COVID-19 VACCINE. On an unknown date, unknown after receiving Shingles vaccine and Shingles vaccine, the patient experienced vaccination failure (serious criteria GSK medically significant) and shingles. On an unknown date, the outcome of the vaccination failure and shingles were unknown.   It was unknown if the reporter considered the vaccination failure and shingles to be related to Shingles vaccine and Shingles vaccine.  Additional details were provided as follows: The patient had reported for him/herself. The age at vaccination was not reported but the patient was in her/his 8th decades at the time of reporting. After receiving Shingles vaccine and Covid-19 vaccine, the patient got very light cases of shingles twice. The patient stated that, a weakened immune system could cause Shingles.  The patient also stated that, each of us were not like the other and suggested to stop making statements that were based on misinformation. It was unknown if the reporter considered the shingles to be related to Covid-19 vaccine. This case was considered as suspected vaccination failure, since the details regarding time to onset for event and laboratory confirmation of shingles was not provided.
Fatigue or tiredness; This is a spontaneous report from a non-contactable consumer, the patient. A 64-year-old male patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER8727) via an unspecified route of administration in the left arm on 26Mar2021 at 08:00 (at the age of 64-years-old) as a single dose for COVID-19 immunisation. Medical history included COVID-19. Concomitant medications were not reported. The patient had not received any other vaccines within 4 weeks prior to the COVID-19 vaccine. Prior to the vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 27Mar2021, the patient had experienced fatigue or tiredness. No therapeutic measures were taken as the result of adverse events. The clinical outcome of the event fatigue or tiredness was resolved on an unknown date in Mar2021.  No follow-up attempts are needed. No further information is expected.
Patient arrived on 4/15/21 for 2nd dose in vaccine series and reported symptom exacerbation of preexisting  pancreatitis characterized by a familiar pain in the upper right quadrant of anterior abdomen. The pain worsened over the next 2 days and the patient avoided food as a precaution and contacted primary care physician at clinic for advice. Physician advised to monitor pain and ability to eat, and if it became excruciating or persistent to seek emergency medical attention. The patient was again able to eat on the 3rd day (6th day after vaccine) and the pain slowly subsided.
VACCINE EXPOSURE DURING PREGNANCY; This prospective pregnancy case was reported by a healthcare professional and described the occurrence of vaccine exposure during pregnancy in a 35-year-old female subject who was vaccinated with tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed (Boostrix, GlaxoSmithKline) for prophylaxis during pregnancy.   The subject's medical history included two previous pregnancies resulting in two spontaneous abortions.  Prior to becoming pregnant the subject was not using contraception.  On 31 August 2011 the subject received booster dose of Boostrix (.5 unknown units, intramuscular, unknown site), and experienced vaccine exposure during the second trimester of her pregnancy.  The subject was approximately 21 weeks gestation at the time of vaccination.  The conception was reported to be normal.  Date of last menstrual period was 02 April 2011 and estimated date of delivery was 07 January 2012.  Prenatal testing including ultrasound and maternal serum alpha-fetoprotein on 01 August 2011 had revealed no evidence of a defect.   Upon internal review done on 18th September 2019, the pregnancy outcome was updated to lost to follow-up.       Lab Comments: Lab Tests: Ultrasound and maternal serum alpha-fetoprotein on 01 August 2011 revealed no evidence of a defect.
pt devel fever to 103 R on day following DTP, then approx 30 hrs p/DTP had grand-mal sz lasting approx 2 minutes; seen immed @ hosp when pt seemed OK & sepsis work-up nl;
I went to bed that night and I froze, my blood pressure was sky high and the next day it was the same thing, I couldn't walk and at the injection site it hasn't healed, it is still scabby. When I went last week to get my Booster, I got it on the other arm because that second shot never healed.  I still have extremely high blood pressure 200/103 and now is 165/90 which is still high my doctor said.
Pt vaccinated with MMR/Rubella 4 days after became limp, twitching of hand & leg & clenching of teeth. Noted post ictal for few hrs. Duration of episode few min.
Initial report received from nurse (patient) as quality complain on 20 Nov 2009: The nurse had problem of leakage with 10 units of H1N1 (batch no. 102040P1). She reported that vaccine ran down her hand and down her arm. No adverse event was reported. Following an internal review done on 05 Feb 2010 of the data received on 20 Nov 2009 following corrections made: The event coding was changed.
Headache x 3 days post injection .  Treated with OTC Tylenol 500mg, 1/2 cup caffeine.  Swollen lymph node in left armpit starting 2 days post vaccination. Cleansed area with soap and water. Applying warm compress daily. Avoiding deodorant to area.
Hospitalized with multiple COVID symptoms. He has been ill for 5 days with weak and fatigued, not been eating or drinking much, has a cough productive of phlegm, congestion and worsening shortness of breath, headache and generalized malaise and body aches and feeling lightheaded. He was exposed to a former coworker who tested positive for Covid.  He was seen in urgent care and had a positive rapid Covid test. He has received the Covid vaccine. He is anticoagulation therapy for history of A-Fib. He tested positive for Covid in urgent care today.   Admitted to the hospital for further evaluation and treatment.
First shot had Covid arm. 7 days after shot started with itching around site. Next had a dark red circular area around injection site. Arm more sore than right after shot. Went away gradually over 4 day period. Just used cortisone cream.  Second shot was sick with flu like symptoms 12 hours after shot. Got shot in my right arm since I had experienced Covid arm in my left arm with first shot. Symptoms lasted exactly 24 hours ( fever broke). Also noticed swollen lymph nodes in my neck on the sane side as shot. This occurred about 5 days after and went away after few days. Also started to have pain up the back of my neck on both sides. Also tingling sensation around right shoulder area.  Slight occurance of Covid arm but not significant
Itchy red rashes all over the body; Itchy red rashes all over the body; Rashes all over the body; This is a spontaneous report from a non-contactable nurse, the patient. A 39-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: FF2588) via an unspecified route of administration in the left arm on 19Sep2021 at 10:30 (at the age of 39-years-old) as a single dose for COVID-19 immunisation. The patient did not have any relevant medical history. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medication included multivitamins (MANUFACTURER UNKNOWN), for an unknown indication from an unknown date and unknown if ongoing. The patient did not receive any other vaccine within four weeks prior to the COVID-19 vaccine. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: FE3180) via an unspecified route of administration in the left arm on 29Aug2021 at 10:30 (at the age of 39-years-old) as a single dose for COVID-19 immunisation. On 21Sep2021, 2 days after the second dose of vaccine, the patient experienced developed itchy red rashes all over the body. The patient went to an urgent care clinic and was prescribed oral steroids and hydrocortisone (MANUFACTURER UNKNOWN) cream for the rashes. The events had resulted in doctor/other health care professional office/clinic visit and emergency room/department or urgent care. Since the vaccination, the patient had been tested for COVID-19. On 18Sep2021, the patient underwent COVID PCR test (nasal swab) and the result was negative. Therapeutic measures were taken as a result of reported events which included treatment with oral steroids and hydrocortisone (MANUFACTURER UNKNOWN) cream. The clinical outcome of events developed itchy red rashes all over the body was resolving at the time of this report.  No follow-up attempts are possible. No further information is expected.
65 yo presents for follow up of injection site reaction. Not as red this AM, but at bottom looks red underneath. Misshaped circle. Still lumpy in middle. Itchy, no fever. Did not take claritin or benadryl. Did not keep her up. Looks like a localized reaction, cool compresses clartitin, benadryl, follow up for increasing redness, warmth.
This spontaneous report as received from a physician refers to a 21 years old female patient. On an unknown date, the patient was vaccinated with 2 doses of M-M-R II (dose, route of administration and indication were not provided). Other suspect therapy VARIVAX (Merck) 1 dose (dose, route of administration and indication were not provided) was administered on an unspecified date. No concomitants were reported. On an unknown date, the patient developed negative titres for mumps and varicella. Action taken with respect to of M-M-R II and VARIVAX (Merck) was not applicable. No product quality complaint was involved. The outcome of events was unknown. Causality was not provided. No further information provided. Additional information has been requested.
Mom reported pain, swelling, warmth, redness approximately silver dollar size yesterday and one episode of emesis overnight.
This spontaneous report as received from a patient of unknown age and gender, refers to herself/himself. There were no concomitant medications, concurrent conditions and medical history reported. On an unknown date, the patient was vaccinated with ZOSTAVAX (site and route of administration, dose, lot number and expiration date were not reported). On an unknown date in October 2015, the patient came down with shingles. The outcome of the event was not recovered (reported as dealing with the pain at the time of the report). The relatedness between the event and ZOSTAVAX was not reported. Additional information has been requested.
H1N1 vaccine was a one-time dose. Symptoms: Symptoms: 1. RespDepression, 2. DYSPNEA (1/16/10@08-00).
At injection site redness and swelling 6.5 cm x 4 cm. Induration with small amount of bruising. Painful to touch. Patient using ice, Ibuprofen and Benadryl for treatment.
Patient reported pain and swelling at injection site soon after the injection, pain/swelling continued and pt presented to er.  Dr reports pt had significant swelling and pain that continued.